MASIMO CORPORATION for MASIMO CORPORATION
A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 1st Quarter - Report (this page) | Apr 19, 2024 | $90,000 | Replaced |
| 1st Quarter - Amendment | Apr 24, 2024 | $190,000 | Yes |
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Support for monitoring of patients taking opioids, education for patients, providers, caregivers and the public on the dangers of opioids, and patient safety in general; Support of legislation to mandate continuous monitoring for patients taking opioids; Support for policies and legislation to alleviate healthcare worker burnout with the use of medical technology; Patient safety policy and legislation
| Lobbyist | Covered position, as disclosed |
|---|---|
| CATHERINE MEIER | — |
| PAUL ORDAL | — |
Copyright/Patent/Trademark CPT
Issues related to intellectual property rights and anti-competitive behavior in the medical device supply chain; International Trade Commission
| Lobbyist | Covered position, as disclosed |
|---|---|
| CATHERINE MEIER | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.